BioAge Labs

BIOA

시가총액 US$2.22억

Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema (DME).

BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and 86% median hsCRP reduction, with Phase 2 topline data expected in H2 2026. BIOA's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, plus partnerships with Novartis and Eli Lilly, supporting long-term optionality.

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.6 per share a year ago.

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026

BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies.